US drug product landscape: 135,667 NDCs, 49,681 generics, and a 2033 format overhaul

The FDA NDC Directory contains 135,667 listed drug products as of June 10, 2026, spanning 15 marketing categories, hundreds of labelers, and every route from oral to epidural. Of those, 114,160 are finished products ready for commercial distribution. ANDA-filed generics account for 49,681 entries — 36% of the directory — followed by OTC monograph drugs at 35,162 (25%). Unapproved homeopathic products hold a surprising third place at 13,531 (9%), exceeding the combined total of all NDA and BLA products. Oral delivery accounts for 48% of all routes. And the top labeler by NDC count is not a manufacturer at all — it is Bryant Ranch Prepack, a repackager with 4,410 entries.

This analysis is drawn from the FDA National Drug Code (NDC) Directory, a daily-updated database of all drugs listed with the agency under Section 510 of the Federal Food, Drug, and Cosmetic Act. Each NDC is a unique three-segment identifier — labeler code, product code, package code — assigned to every drug manufactured, prepared, propagated, compounded, or processed for commercial distribution in the United States. The directory covers prescription drugs, over-the-counter products, approved and unapproved drugs, active pharmaceutical ingredients, and repackaged or relabeled products. A single drug product listed in multiple package configurations generates multiple NDCs, so the count reflects package-level entries rather than distinct molecular entities.

Marketing category breakdown: where the volume lives

Three categories — ANDA, OTC monograph, and bulk ingredients — account for 72% of all NDCs. The ANDA dominance reflects the mature generic drug market in the United States: every approved generic filing generates NDCs for each strength, dosage form, and package size. The OTC monograph figure captures the vast tail of non-prescription products — sunscreens, antacids, topical antiseptics — that do not require individual premarket approval but must be listed.

The unapproved homeopathic category demands attention. At 13,531 entries, it surpasses NDA products (7,431) by nearly two to one. These products are listed under FDA's compliance policy but lack approved applications. In 2022, FDA proposed a framework to regulate homeopathic drugs more stringently, but the category continues to generate NDC listings at volume, representing a significant portion of products that exist in a regulatory gray zone.

The NDA authorized generic category (1,191 entries) captures brand-name drugs marketed under their own NDA but without brand trade dress — typically at a lower price point to compete with ANDA generics. These represent a strategic choice by innovators to capture generic market share while maintaining NDA-level regulatory exclusivity.

Brand vs. generic: a near-even split among finished products

Among the 114,160 finished drug products, branded entries hold a narrow majority over generic and unbranded entries. The closeness of this split is notable: despite ANDA products comprising 36% of the total directory by marketing category, generic NDCs represent 47% of finished products. The gap reflects the fact that many OTC monograph products and unapproved drugs carry brand names, inflating the branded count even without NDA or BLA backing.

For market access teams, this means that roughly half the NDC universe — the generic side — is subject to competitive pricing pressure and multi-source dispensing, while the other half operates under varying degrees of brand premium. The branded figure, however, overstates the innovator-segment opportunity: it includes homeopathic brands, OTC consumer brands, and repackaged products that carry trade names without patent or exclusivity protection.

Dosage form landscape: solid oral dominates, powders surprise

Solid oral dosage forms dominate. Combining plain tablets (18,608), film-coated tablets (11,849), extended-release tablets (2,361), coated tablets (1,540), chewable tablets (1,464), and capsules (6,819) plus liquid-filled capsules (1,478) yields over 44,000 NDCs — roughly one-third of the entire directory. This concentration reflects both the manufacturing economics of oral solid dosage and the regulatory efficiency of filing ANDAs for well-characterized tablet formulations.

Powder (15,468) is the second-largest category, driven partly by bulk ingredient listings and partly by oral powder reconstitution products used in compounding and homeopathic formulations. Pellets (7,587) are overwhelmingly homeopathic — a dosage form that barely registers in prescription markets but accounts for a significant share of the NDC directory's volume due to the homeopathic category's 13,531 entries.

Injectable products — combining injection, solution (5,266) and injection (2,788) — total just over 8,000 NDCs. Despite their clinical importance and higher per-unit revenue, sterile injectables represent only 6% of NDC volume, reflecting the higher manufacturing barriers and tighter regulatory requirements for parenteral products.

Route of administration: oral nearly half the directory

Oral and topical routes together account for 68.6% of all NDC entries. The oral dominance (48.4%) tracks the solid oral dosage form concentration. The topical figure (20.2%) is inflated by OTC products — creams, lotions, ointments, and gels that represent the long tail of consumer health products listed under the OTC monograph system.

Parenteral routes — intravenous (5.1%), subcutaneous (2.8%), and intramuscular (1.8%) — collectively account for 9.7% of NDCs. These are the routes that drive specialty pharmacy revenue, cold-chain logistics, and the biologics market. For supply chain operators, the relatively small number of parenteral NDCs (roughly 13,250) compared to their disproportionate share of drug spending underscores the pricing power that attaches to injectable and biologic products.

DEA schedule distribution: controlled substances by the numbers

Schedule II controlled substances lead with 2,264 NDCs — more than CIV (2,156), CIII (955), and CV (917) individually. The total across all schedules is 6,304, representing 4.6% of the directory. The 12 CI entries are likely research or manufacturing-related listings for substances with no approved medical use. For pharmacy operations and wholesale distributors, the CII count matters because these products carry the strictest handling, storage, and reporting requirements under the Controlled Substances Act and DSCSA serialization mandates.

The CIV count (2,156) is noteworthy for its proximity to CII — driven largely by benzodiazepines and similar anxiolytics that have proliferated in generic form. Each generic approval for a diazepam or alprazolam product generates NDCs for every strength and package size, pushing the CIV total upward.

Top 20 labelers: repackagers dominate NDC volume

The labeler ranking reveals a supply chain where repackaging and redistribution generate more NDCs than original manufacturing. Bryant Ranch Prepack (4,410) and A-S Medication Solutions (2,709) are unit-dose repackagers — they purchase drugs in bulk and repackage them into pharmacy-ready unit doses, each requiring its own NDC. Proficient Rx LP (1,702), REMEDYREPACK (1,394), NuCare (1,005), PD-Rx (819), Aphena (776), and American Health Packaging (648) serve a similar function. Together, repackagers and relabelers account for roughly seven of the top 20 labeler positions.

Hahnemann Laboratories (4,403) and Boiron (2,033) are homeopathic manufacturers — together they hold nearly 6,500 NDCs, almost entirely within the UNAPPROVED HOMEOPATHIC category. Greer Laboratories (1,328) specializes in allergen extracts. These three firms account for a disproportionate share of directory entries without representing the prescription pharmaceutical market that drives most drug spending.

Among actual generic manufacturers, Aurobindo (1,887), Zydus (711), Hikma (706), Fresenius Kabi (693), and Sun Pharma (665) are the most prominent. Procter & Gamble (766) represents the OTC consumer health segment. The absence of the largest innovator companies — Pfizer, Johnson & Johnson, Merck — from the top 20 reflects a structural feature of the NDC system: branded innovators typically file fewer NDCs because each branded product is a single molecule with limited package configurations, whereas generic manufacturers file separate ANDAs for every strength and dosage form of every reference product they target.

Listing expiration: a two-year concentration

NDC listing expirations cluster heavily in 2026, with 101,704 entries (75%) carrying a 2026 expiration date. This does not mean three-quarters of US drug products will disappear; NDC listings must be renewed periodically, and the 2026 cluster reflects the directory's listing renewal cycle. The 30,057 entries with 2027 expirations represent listings filed or renewed more recently. For supply chain planners, this concentration signals that most NDC data requires regular revalidation — listings can lapse if labelers fail to update their submissions, potentially creating gaps in formulary databases and claims adjudication systems.

The 12-digit NDC transition: what the format overhaul means

On March 5, 2026, FDA published a final rule standardizing the National Drug Code to a uniform 12-digit format (6-4-2), replacing the current system of three variable 10-digit configurations (4-4-2, 5-3-2, 5-4-1). The rule takes effect March 7, 2033, with a three-year transition period through March 2036.

For the 135,667 products in the current directory, the transition is a ministerial change — existing 10-digit NDCs convert to 12 digits by adding leading zeros. FDA has stated this does not constitute a new NDC assignment. But the operational implications are substantial. Every pharmacy system, claims adjudication platform, wholesaler database, electronic health record, and DSCSA serialization workflow must handle both 10-digit and 12-digit formats during the transition. The 6-digit labeler code expansion adds approximately 900,000 new labeler codes — a roughly 900-year supply — addressing an exhaustion concern that projected FDA would run out of 5-digit labeler codes by the mid-2030s.

The rule also permits nonlinear (2D) barcodes on drug labels, aligned with DSCSA product identifier requirements. A single 2D data matrix barcode can encode the 12-digit NDC alongside serial number, lot, and expiration date — potentially simplifying label design and scanner infrastructure for manufacturers already deploying serialization systems.

For the generic manufacturers and repackagers that dominate NDC volume, the format change means updating label artwork, resubmitting SPL files, and coordinating with trading partners across the supply chain. The seven-year runway before the effective date reflects the scale of that coordination across the 135,667 entries — and the thousands more that will be added before 2033.

Sources

• FDA National Drug Code (NDC) Directory, accessed June 10, 2026. (fda.gov)
• FDA. "Revising the National Drug Code Format and Drug Label Barcode Requirements." Federal Register, March 5, 2026, 91 FR 10749. (federalregister.gov)
• FDA. "National Drug Code Format." (fda.gov)
• FDA. "Revising the National Drug Code Format and Drug Label Barcode Requirements; Final Regulatory Impact Analysis." (fda.gov)
• Drug Listing Act of 1972, Section 510 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).